publication date: May. 1, 2015
20150501 - May. 1, 2015
ISSUE 17 – MAY 1, 2015PDF

Thumbs Up on Amgen’s T-VEC to Treat Melanoma; Is it Local Therapy for Systemic Disease?

An FDA advisory committee April 29 recommended approval of a metastatic melanoma treatment based on an attenuated Herpes Simplex Virus-1.

In a joint meeting, the agency’s Oncologic Drugs Advisory Committee and its Cellular, Tissue, and Gene Therapies Advisory Committee voted 22 to 1 to recommend full approval for talimogene laherparepvec, sponsored by Amgen Inc.

At the contentious all-day meeting, which ran twice as long as a standard session of ODAC, the unusually large group of advisors summoned by the FDA didn’t get the opportunity to clearly identify the group of patients who stand to benefit from the agent, also called T-VEC, or specify the agent’s place in a sequence of melanoma treatments.

NIH Slated to Receive $10 Billion Increase In Second 21st Century Cures Draft Bill

The House Committee on Energy and Commerce published the second “discussion draft” for a comprehensive bipartisan initiative aimed at streamlining development of drugs and medical devices.

The proposed legislation, called “21st Century Cures,” was launched April 30, 2014, and is led by Rep. Fred Upton (R-Mich.), chairman of the committee, and Rep. Diana DeGette (D-Colo.), chief deputy whip.

In addition to boosting NIH funding by $10 billion over five years and establishing a clinical trial data system for federally funded trials, the discussion draft includes provisions for developing the next line of antibiotics.

Institute of Medicine to Become National Academy of Medicine

The membership of the National Academy of Sciences voted April 28 at its 152nd annual meeting to change the name of the Institute of Medicine to the National Academy of Medicine, effective July 1.

The National Academy of Medicine will continue to be an honorific society and will inherit the more than 1,900 current elected members and foreign associates of the IOM.

 

Letter to the Editor

MD Anderson Administration Behaves as a “Financially Privileged Elitist Group”

To the Editor:

Congratulations on your outstanding article entitled “MD Anderson Execs Get Big Raises In the Midst of Faculty Morale Woes.” As a 35-year faculty member of the MD Anderson Cancer Center, now retired, I am deeply disturbed at the endangered reputation of one of the greatest institutions of its kind in the world. Every other month seems to bring some embarrassing new revelation at the hands of the current leadership.

 

An Appreciation

Mike Katz, 61, Advocate, Educator

By Michael D. Scott

The cancer field is filled with advocates—advocates for research into specific forms of malignancy, advocates for access to care for patients with limited resources, advocates for pediatric cancers—you name it. Many of these people are motivated, passionate, determined, and successful in moving their specific agendas forward in the interests of patients, clinicians, researchers, and others.

In Brief

  • Margaret Kripke to retire as CPRIT chief scientist

  • CPRIT to award two grants

  • ASCO Conquer Cancer Foundation names annual award winners

  • Karmanos Cancer Institute raises $2.8 million at annual dinner
  • IU Simon Cancer Center raises $720,000 at CHUCKSTRONG tailgate gala
  • Dana-Farber, Harvard School of Public Health, and Irish Cancer Society form collaboration
  • St. Jude forms affiliate with Novant Health
  • Geisinger Health System opens precision medicine center
Drugs and Targets

  • FDA grants orphan designation to Reolysin in malignant glioma

  • Paclical receives market authorization in Russian Federation

  • Celgene International II Sarl forms collaboration with MedImmune

Copyright (c) 2020 The Cancer Letter Inc.